Update in the Treatment of the Complications of Cirrhosis

D'Amico, 2006, Natural history and prognostic indicators of survival in cirrhosis. A systematic review of 118 studies, J Hepatol, 44, 217, 10.1016/j.jhep.2005.10.013 D'Amico, 2014, Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients, Aliment Pharmacol Ther, 39, 1180, 10.1111/apt.12721 Ripoll, 2007, Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis, Gastroenterology, 133, 481, 10.1053/j.gastro.2007.05.024 Allen, 2022, Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design, J Hepatol, 77, 1237, 10.1016/j.jhep.2022.07.004 Bruno, 2013, Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy, Am J Gastroenterol, 108, 1112, 10.1038/ajg.2013.110 Zacharias, 2018, Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices, Cochrane Database Syst Rev, 10, CD011510 Villanueva, 2019, Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 393, 1597, 10.1016/S0140-6736(18)31875-0 de Franchis, 2022, Baveno VII - renewing consensus in portal hypertension, J Hepatol, 76, 959, 10.1016/j.jhep.2021.12.022 Abraldes, 2016, Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “Anticipate” study, Hepatology, 64, 2173, 10.1002/hep.28824 Pons, 2021, Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease, Am J Gastroenterol, 116, 723, 10.14309/ajg.0000000000000994 Rabiee, 2022, Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: validation of ANTICIPATE models and development of a lab-based model, Hepatol Commun, 6, 3324, 10.1002/hep4.2091 Sinagra, 2014, Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis, Aliment Pharmacol Ther, 39, 557, 10.1111/apt.12634 Graham, 1981, The course of patients after variceal hemorrhage, Gastroenterology, 80, 800, 10.1016/0016-5085(81)90144-X D'Amico, 2003, Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators, Hepatology, 38, 599, 10.1053/jhep.2003.50385 Reverter, 2014, A MELD-based model to determine risk of mortality among patients with acute variceal bleeding, Gastroenterology, 146, 412, 10.1053/j.gastro.2013.10.018 Monescillo, 2004, Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding, Hepatology, 40, 793, 10.1002/hep.20386 Garcia-Pagan, 2013, Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study, J Hepatol, 58, 45, 10.1016/j.jhep.2012.08.020 Hussain, 2022, Does preemptive transjugular intrahepatic portosystemic shunt improve survival after acute variceal bleeding? Systematic review, meta-analysis, and trial sequential analysis of randomized trials, J Gastroenterol Hepatol, 37, 455, 10.1111/jgh.15714 Nicoară-Farcău, 2021, Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data, Gastroenterology, 160, 193, 10.1053/j.gastro.2020.09.026 Boike, 2022, North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension, Clin Gastroenterol Hepatol, 20, 1636, 10.1016/j.cgh.2021.07.018 Lv, 2018, Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial, Gut, 67, 2156, 10.1136/gutjnl-2017-314634 Conn, 1982, Propranolol in the treatment of portal hypertension: a caution, Hepatology, 2, 641 Serste, 2010, Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites, Hepatology, 52, 1017, 10.1002/hep.23775 Krag, 2012, The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease, Gut, 61, 967, 10.1136/gutjnl-2011-301348 Chirapongsathorn, 2016, Nonselective beta-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 14, 1096, 10.1016/j.cgh.2016.01.012 Kumar, 2019, Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial, Hepatol Int, 13, 800, 10.1007/s12072-019-09986-9 Tergast, 2019, Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis, Aliment Pharmacol Ther, 50, 696, 10.1111/apt.15439 Henry, 2021, AGA clinical practice update on management of bleeding gastric varices: expert review, Clin Gastroenterol Hepatol, 19, 1098, 10.1016/j.cgh.2021.01.027 Lee, 2019, Management options for gastric variceal hemorrhage, JAMA Surg, 154, 540, 10.1001/jamasurg.2019.0407 Luo, 2021, Endoscopic cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration for prevention of gastric variceal bleeding: a randomized controlled trial, Hepatology, 74, 2074, 10.1002/hep.31718 Villanueva, 2021, Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis, J Hepatol, 75, 589, 10.1016/j.jhep.2021.04.022 Biggins, 2021, Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases, Hepatology, 74, 1014, 10.1002/hep.31884 2018, EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis, J Hepatol, 69, 406, 10.1016/j.jhep.2018.03.024 Morando, 2015, Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study, Liver Int, 35, 1508, 10.1111/liv.12583 Bai, 2014, TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis, World J Gastroenterol, 20, 2704, 10.3748/wjg.v20.i10.2704 Bureau, 2017, Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites, Gastroenterology, 152, 157, 10.1053/j.gastro.2016.09.016 Caraceni, 2018, Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial, Lancet, 391, 2417, 10.1016/S0140-6736(18)30840-7 Sola, 2018, Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial, J Hepatol, 69, 1250, 10.1016/j.jhep.2018.08.006 Bernardi, 2012, Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials, Hepatology, 55, 1172, 10.1002/hep.24786 Singh, 2012, Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study, J Hepatol, 56, 348, 10.1016/j.jhep.2011.04.027 Singh, 2013, Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study, Am J Gastroenterol, 108, 560, 10.1038/ajg.2013.9 Macken, 2022, Palliative long-term abdominal drains for the management of refractory ascites due to cirrhosis: a consensus document, Frontline Gastroenterol, 13, e116, 10.1136/flgastro-2022-102128 Lepida, 2019, Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites, Aliment Pharmacol Ther, 50, 978, 10.1111/apt.15502 Caraceni, 2021, The search for disease-modifying agents in decompensated cirrhosis: from drug repurposing to drug discovery, J Hepatol, 75, S118, 10.1016/j.jhep.2021.01.024 Wu, 2022, The digital transformation of hepatology: the patient is logged in, Hepatology, 75, 724, 10.1002/hep.32329 Angeli, 2015, Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites, J Hepatol, 62, 968, 10.1016/j.jhep.2014.12.029 Cavallin, 2015, Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial, Hepatology, 62, 567, 10.1002/hep.27709 Wong, 2021, Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome, N Engl J Med, 384, 818, 10.1056/NEJMoa2008290 Singh, 2012, Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study, J Hepatol, 56, 1293, 10.1016/j.jhep.2012.01.012 Arora, 2020, Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure, Hepatology, 71, 600, 10.1002/hep.30208 Cavallin, 2016, Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study, Hepatology, 63, 983, 10.1002/hep.28396 Trawale, 2010, The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study, Liver Int, 30, 725, 10.1111/j.1478-3231.2009.02182.x Vilstrup, 2014, Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver, Hepatology, 60, 715, 10.1002/hep.27210 2022, EASL Clinical Practice Guidelines on the management of hepatic encephalopathy, J Hepatol, 77, 807, 10.1016/j.jhep.2022.06.001 Rose, 2020, Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy, J Hepatol, 73, 1526, 10.1016/j.jhep.2020.07.013 Vierling, 2016, Fasting blood ammonia predicts risk and frequency of hepatic encephalopathy episodes in patients with cirrhosis, Clin Gastroenterol Hepatol, 14, 903, 10.1016/j.cgh.2015.11.018 Tranah, 2022, Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis, J Hepatol, 77, 1554, 10.1016/j.jhep.2022.07.014 Rockey, 2014, Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy, Hepatology, 59, 1073, 10.1002/hep.26611 Trebicka, 2021, The microbiota in cirrhosis and its role in hepatic decompensation, J Hepatol, 75, S67, 10.1016/j.jhep.2020.11.013 Bajaj, 2013, Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy, PLoS One, 8, 10.1371/journal.pone.0060042 Bajaj, 2014, Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis, Aliment Pharmacol Ther, 39, 1113, 10.1111/apt.12695 Dhiman, 2014, Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial, Gastroenterology, 147, 1327, 10.1053/j.gastro.2014.08.031 Bajaj, 2019, Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial, Hepatology, 70, 1690, 10.1002/hep.30690 Hirode, 2019, Increasing burden of hepatic encephalopathy among hospitalized adults: an analysis of the 2010-2014 National Inpatient Sample, Dig Dis Sci, 64, 1448, 10.1007/s10620-019-05576-9 Romero-Gomez, 2015, Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure, J Hepatol, 62, 437, 10.1016/j.jhep.2014.09.005 Cordoba, 2014, Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF), J Hepatol, 60, 275, 10.1016/j.jhep.2013.10.004 Tapper, 2022, Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States, J Hepatol, 77, 377, 10.1016/j.jhep.2022.02.010 Mangini, 2021, New therapies of liver diseases: hepatic encephalopathy, J Clin Med, 10, 4050 Butterworth, 2019, LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses, Drugs, 79, 31, 10.1007/s40265-018-1024-1 Fagan, 2022, A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study, J Hepatol, 78, 312, 10.1016/j.jhep.2022.09.009 Riggio, 2005, Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study, J Hepatol, 42, 674, 10.1016/j.jhep.2004.12.028 Bureau, 2021, The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt : a randomized controlled trial, Ann Intern Med, 174, 633, 10.7326/M20-0202 Bajaj, 2023, Dosing of rifaximin soluble solid dispersion tablets in adults with cirrhosis: 2 randomized, placebo-controlled trials, Clin Gastroenterol Hepatol, 21, 723, 10.1016/j.cgh.2022.05.042